NMG
BMY icon

New Millennium Group’s Bristol-Myers Squibb BMY Stock Holding History

New Millennium Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$177K Buy
3,285
+3,240
+7,200% +$156K 0.08% 67
2025
Q3 		$2.01K Buy
45
+1
+2% +$47 ﹤0.01% 318
2025
Q2 		$2.03K Buy
44
+1
+2% +$49 ﹤0.01% 316
2025
Q1 		$2.65K Sell
43
-11
-20% -$641 ﹤0.01% 315
2024
Q4 		$3.05K Buy
54
+12
+29% +$670 ﹤0.01% 345
2024
Q3 		$2.2K Hold
42
– – ﹤0.01% 296
2024
Q2 		$1.74K Buy
+42
New +$1.88K ﹤0.01% 309
2024
Q1 		– Sell
-41
Closed -$2.1K – 107
2023
Q4 		$2.1K Sell
41
-97
-70% -$5.09K ﹤0.01% 319
2023
Q3 		$8.03K Buy
138
+67
+94% +$4.11K 0.01% 179
2023
Q2 		$4.54K Sell
71
-299
-81% -$20.1K ﹤0.01% 227
2023
Q1 		$25.7K Sell
370
-34
-8% -$2.4K 0.03% 139
2022
Q4 		$29.1K Buy
404
+22
+6% +$1.66K 0.03% 128
2022
Q3 		$27K Sell
382
-21
-5% -$1.52K 0.03% 125
2022
Q2 		$31K Buy
+403
New +$30.7K 0.03% 123

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

New Millennium Group's BMY Position: Q4 2025 in Review

New Millennium Group increased its Bristol-Myers Squibb (BMY) stake by 7,200% in Q4 2025, buying an estimated $156K and bringing the position to 3,285 shares worth $177K. The position accounts for 0.08% of the portfolio, ranked #67.

New Millennium Group first reported a position in BMY in Q2 2022 and has held it in 14 quarters since. 2,447 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

  • New Millennium Group held 3,285 shares of Bristol-Myers Squibb worth $177K as of Q4 2025.
  • New Millennium Group bought 3,240 Bristol-Myers Squibb shares in Q4 2025, an estimated $156K.
  • Bristol-Myers Squibb made up 0.08% of New Millennium Group's portfolio in Q4 2025, its #67 holding.
  • New Millennium Group first reported a position in Bristol-Myers Squibb in Q2 2022 and has held it in 14 quarters since.
  • 2,447 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on New Millennium Group's 13F filing for Q4 2025, filed 6 Feb 2026.